Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Stock Analysis

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is a publicly traded company in the FINANCIAL SERVICES sector. It trades at $10.61, carries a market capitalization of $257.33M, a price-to-earnings ratio of 53.00. This page summarizes the public market data, fundamentals, and frequently asked questions for DMAA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: FINANCIAL SERVICES - SHELL COMPANIES

Exchange: NASDAQ

Key Metrics

• Price: $10.61
• Market Cap: $257.33M
• P/E Ratio: 53.00
• EPS: $0.20
• 52-Week High: $10.61
• 52-Week Low: $10.15

About Drugs Made In America Acquisition Corp. Ordinary Shares

None

GNG Research Analysis

GNG Research scores Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for DMAA.

Frequently Asked Questions

Does DMAA pay dividends?

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) does not currently pay a regular dividend.

What is DMAA's P/E ratio?

Drugs Made In America Acquisition Corp. Ordinary Shares has a price-to-earnings (P/E) ratio of 53.00.

What is DMAA's market cap?

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a market capitalization of $257.33M with a current stock price of $10.61.